This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Contraindications administration of intramuscular (IM)/subcutaneous (SC) medroxyprogesterone acetate (DMPA) injection

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Criteria for Exclusion (1):

  • Consent not given.
  • Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
  • Individuals 16 years of age and over and assessed as lacking capacity to consent.
  • Known or suspected pregnancy.
  • Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics.
  • Unexplained vaginal bleeding suspicious of a serious medical condition.
  • Acute porphyria

Cardiovascular Disease

  • Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic attack.
  • Individuals with multiple risk factors for cardio-vascular disease (such as smoking, diabetes, hypertension, obesity and dyslipidaemias)
  • Hypertension with vascular disease.

Cancers

  • Current or past history of breast cancer.
  • Benign liver tumour (hepatocellular adenoma).
  • Malignant liver tumour (hepatocellular carcinoma).

Gastro-intestinal conditions

  • Severe decompensated cirrhosis.

Interacting medicines – see current British National Formulary (BNF) www.bnf.orgor individual product SPC http://www.medicines.org.uk

Reference:

  • Patient Group Direction (PGD) (NHS Specialist Pharmacy Service).Administration of intramuscular (IM) medroxyprogesterone acetate (DMPA) injection . (Accessed 17th March 2021).

 

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.